Indivior introduces generic version of its Suboxone opioid drug
Category: #health  By Pankaj Singh  Date: 2019-02-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

Indivior introduces generic version of its Suboxone opioid drug
  • The company said its launch of an authorize generic version of the drug would prompt other firms to introduce their own cheaper versions
  • The announcement comes in backdrop of a court ruling that allowed its rivals to sell generic versions of the drug

British pharmaceutical firm Indivior Plc has reportedly introduced a generic version of its highly-successful opioid addiction drug Suboxone in the U.S. As per trusted sources, the announcement comes in backdrop of a court ruling that allowed its rivals to sell generic versions of the drug.

Reportedly, the U.S. Supreme Court cleared the way for a cheaper version of the drug marketed by India-headquartered generic drug maker Dr. Reddy’s Laboratories. According to a report published by Business Standard, Indivior has spent more than two years in fighting court battles and patent lawsuits in the United States with firms including Mylan, Teva, and Dr. Reddy’s Laboratories to prevent them from introducing generic version of its drugs.

Indivior has reportedly stated that the launch of an authorized generic drug may prompt other firms to introduce their own cheaper versions of the drug. The British drug maker had said in December last year that it was contemplating to launch a cheaper version of Suboxone under its multi-phase contingency strategy to reduce market share losses owing to its generic rivals. If reports are to be believed, Indivior is slated to garner tens of millions of dollars from its generic drug.

Sources familiar with the development claim that launching generic versions of one’s own drugs is quite rare. The U.S. pharmaceutical firm Mylan NV launched its first generic version of allergy auto-injector EpiPen in 2016 following a backlash over the price of the drug.

Indivior’s shares have fallen almost 80% since the generics of Mylan and Dr. Reddy’s Laboratories were first approved by U.S. regulators in June 2018.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Rogers Communications launches 5G network services across Canada
Rogers Communications launches 5G network services across Canada
By Pankaj Singh

  The network will first be implemented in Toronto, Vancouver, Montreal and Ottawa Rogers has collaborated with Ericsson to provide the required technology to develop the network Rogers Communications – a Toronto based telecommunicat...

Amazon orders StreetScooter electric vans to fuel carbon neutral goals
Amazon orders StreetScooter electric vans to fuel carbon neutral goals
By Pankaj Singh

Amazon has ordered about 40 electric vans from Deutsche Post’s StreetScooter in Munich   The Work L delivery van shall be debuted in two of the urban U.S. markets from spring 2020 Amazon.com has reportedly ordered about 40 electric v...

Oyster Point Pharma attains primary endpoint in MYSTIC trial
Oyster Point Pharma attains primary endpoint in MYSTIC trial
By Pankaj Singh

A clinical-stage biopharmaceutical company, Oyster Point Pharma, Inc. recently announced positive results from its Phase 2 MYSTIC clinical study for Dry Eye Disease. For the record, Oyster Point Pharma is focused upon discovering, developing, and co...